Clinical Research Directory
Browse clinical research sites, groups, and studies.
CAR-T Immunotherapy Targeting CD19- ALL
Sponsor: Shenzhen Geno-Immune Medical Institute
Summary
This study will evaluate safety and efficacy of a combination of 4th generation chimeric antigen receptor gene-modified T cells targeting CD19 negative ALL that express CD22, CD123, CD38, CD10, CD20 and TSLPR, as many patients developed CD19-negative disease after CD19 CART immunotherapy. Clinical response and development of a standardized lentiviral vector and cell production protocol will be investigated. This is a phase I/II trial enrolling patients from multiple clinical centers.
Official title: CART Immunotherapy Targeting CD19 Negative Acute Lymphoblastic Leukemia
Key Details
Gender
All
Age Range
6 Months - 75 Years
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2025-07-15
Completion Date
2029-12-15
Last Updated
2026-06-23
Healthy Volunteers
No
Conditions
Interventions
4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR
4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR Patients who have relapsed after CD19 CART immunotherapy or have CD19 negative B cell malignancies
Locations (1)
Shenzhen Geno-immune Medical Institute
Shenzhen, Guangdong, China